A recent JAMA Psychiatry study found that an ADHD medicine called lisdexamfetamine reduced the risk of hospitalization due to amphetamine or methamphetamine addiciton by 18% and 14% for deaths caused by substance abuse disorders.
Subscribe to:
Post Comments (Atom)
< + > Buy or Sell: Medical AI Assistant Edition – Healthcare IT Today Podcast Episode 170
For the 170th episode of the Healthcare IT Today Podcast , we are doing another round of Buy or Sell! For these episodes, we select a health...
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
-
Robert Connely of Pega says patching legacy systems will give way to true health IT modernization, a security breakthrough will lead artific...
No comments:
Post a Comment